In one study of 302 immune thrombocytopenia patients receiving eltrombopag, 3 of the 19 cases of thrombosis occurred during periods of thrombocytosis, generating the hypothesis that thrombocytosis may be associated with a higher thrombotic risk.78 Therefore, we suggest adequate dosing of TPO-RAs to avoid thrombocytosis. Here, TPO is linked to thrombocytosis disease.